Showing results (1-10 of 45) with videos related to
Sort By:
Pageof 5
Human Vaccines & Immunotherapeutics|July 10, 2020
PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potentialTianrui Yang, Ziren Kong, Wenbin MaHuman Vaccines & Immunotherapeutics|November 1, 2017
Vaccination in the immunotherapy of glioblastomaZiren Kong, Yu Wang, Wenbin MaClinical Nuclear Medicine|October 5, 2019
FDG PET/CT Image for a Rosai-Dorfman Disease With Pituitary and Bone Involvement in a Pediatric PatientZiren Kong, Yu Wang, Wenbin Ma, et al.BMC Endocrine Disorders|June 11, 2020
Role of 18F-fluorodeoxyglucose (FDG) and 18F-2-fluorodeoxy sorbitol (FDS) in autoimmune hypophysitis: a case reportZiren Kong, Yu Wang, Wenbin Ma, et al.Frontiers in Oncology|November 7, 2022
The role of PET/CT in radiotherapy for nasopharyngeal carcinomaHongjia Li, Ziren Kong, Yongbo Xiang, et al.Journal of Child Neurology|June 1, 2018
Central Nervous System Germ Cell Tumors: A Review of the LiteratureZiren Kong, Yaning Wang, Congxin Dai, et al.Archives of Oral Biology|May 22, 2012
The role of odontogenic genes and proteins in tooth epithelial cells and their niche cells during rat tooth root developmentYaneng Ge, Ziren Kong, Yongwen Guo, et al.Molecular Pharmaceutics|August 17, 2022
86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer DiagnosisJie Ding, Mengxin Xu, Junyi Chen, et al.Clinical Nuclear Medicine|November 19, 2020
Quantitative Features From CHO PET Distinguish the WHO Grades of Primary Diffuse GliomaZiren Kong, Chendan Jiang, Delin Liu, et al.EJNMMI Research|April 18, 2022
Larger 18F-fluoroboronotyrosine (FBY) active volume beyond MRI contrast enhancement in diffuse gliomas than in circumscribed brain tumorsZiren Kong, Zhu Li, Junyi Chen, et al.Pageof 5